HALO WACC: 7.27% for Halozyme Therapeutics, Inc.
Current inputs imply a 8.71% cost of equity and a 2.00% pre-tax cost of debt. Use this discount rate as a starting point for DCF validation.
WACC Calculator
Values are automatically populated from real data. You can adjust them manually if needed.
Please enter a valid company ticker to calculate WACC
Halozyme Therapeutics, Inc. (HALO) WACC in context
Halozyme Therapeutics, Inc. (HALO) currently screens with an estimated WACC of 7.27%. That blends a 8.71% cost of equity, a 2.00% pre-tax cost of debt, and a 79.77% equity weight into the discount rate you would typically use in a DCF model.
screens as a relatively low discount rate, which usually supports higher DCF values.
A 7.27% discount rate screens as a relatively low discount rate, which usually supports higher DCF values.
This page combines CAPM-based cost of equity with SEC-derived debt and capital structure inputs. The current beta is 1.00 and equity accounts for 79.77% of capital.
Validate business quality on the company page, then carry the same discount-rate assumptions into the DCF page to test fair value sensitivity.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.